Dorsey & Whitney Trust CO LLC decreased its stake in Astrazeneca Plc (NYSE:AZN – Free Report) by 33.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 22,428 shares of the company’s stock after selling 11,504 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Astrazeneca were worth $3,936,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of AZN. Brighton Jones LLC boosted its stake in Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC boosted its stake in Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after buying an additional 11,690 shares in the last quarter. Amundi boosted its stake in Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock valued at $731,000 after buying an additional 3,618 shares in the last quarter. Jump Financial LLC boosted its stake in Astrazeneca by 898.4% in the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock valued at $2,339,000 after buying an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in Astrazeneca by 1.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after buying an additional 559 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.
Analyst Ratings Changes
Several brokerages recently commented on AZN. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $205.33.
Astrazeneca Trading Down 2.5%
Shares of AZN opened at $178.87 on Thursday. The stock has a fifty day moving average price of $190.12 and a two-hundred day moving average price of $185.76. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The company has a market cap of $277.42 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 1.60 and a beta of 0.25.
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Analysts predict that Astrazeneca Plc will post 9.37 EPS for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
